There is a temporary production constraint to secure custom moulding for plastics to resolve and to finalise quality control of the initial first-generation production. The Company has completed initial production of its first-generation product and is currently commissioning the production capacity for its second-generation product with production to commence later this month. The five-year approval from Indonesia's Ministry of Health provides Indonesia's 270 million population with exactly that: access to an accurate Covid-19 diagnostic at an affordable price." This is key in all efforts aimed at mitigating transmission, particularly in areas with a large unvaccinated population. "One of the basic conditions we have to create is giving people access to affordable and accurate rapid tests. Regular Covid-19 testing and screening should be an essential part of our lives as variants continue to hinder global recovery", said Steven Goh, CEO of Achiko AG. "As we've seen, vaccinations alone cannot be the only approach to living with Covid-19.
This will allow Achiko to profitably produce its second-generation AptameX test kits for as little as USD$2.50 per test or less with a production capacity that is able to scale to tens of millions of kits per month as a function of commissioning capacity in plastics. Following approval of the first-generation product, the Company further optimised the test kit using a simpler supply and manufacturing chain in Taiwan and Indonesia.
FOKUS DIAGNOSTIC INDONESIA REGISTRATION
In August 2021, Achiko's manufacturing partner PT Indofarma TBK ("Indofarma") received product registration approval in Indonesia for the Company's first generation AptameX test kit.
FOKUS DIAGNOSTIC INDONESIA FULL
53 LR - Achiko AG (SWX: ACHI, ISIN CH0522213468) through PT Achiko Medika Indonesia ("Achiko", the "Company") is pleased to announce that the Ministry of Health of the Republic of Indonesia has granted full product registration approval for its optimised, second-generation Covid-19 rapid test AptameX TM, alongside its sister digital passporting service, Teman Sehat TM ("Health Buddy"). Zurich, 8 December 2021: Ad hoc announcement pursuant to Art.
AptameX second-generation samples being sent elsewhere in Asia, MENA and eastern Europe for product sampling and demonstrations with the ambition of starting commercialisation outside Indonesia as soon as possible CE Mark filing is dependent on selecting a site to complete the clinical investigation report which is in the process of being secured Production of the second-generation AptameX kits to commence this month Second-generation of AptameX, Achiko's innovative DNA aptamer diagnostic test for Covid-19 has received full approval in Indonesia for five years Optimised second-generation Covid-19 diagnostic test receives full product registration approval in Indonesia
0 kommentar(er)
